mutations, in whom rituximab appears to obtain minor additional value.fifty nine Other genomic subgroups, for example individuals with BIRC3This methylation profile is now obtained in the MBL stage3 and continues to be somewhat stable after some time. However, some CLL have intratumor variability in specific locations, which can change the expressi